Masako Ohno

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy

Junichi Azuma, Masako Ohno, Ryuji Kubota et al. · European Journal of Clinical Pharmacology · 2012 · 266 citations · Full text

Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.

Masako Ohno, Ichiro Yamaguchi, Itiro Yamamoto et al. · PubMed · 2000 · 255 citations

Tuberculosis Prevention, Pathology, Pharmacotherapy +19

Effect of the <i>CYP2D6*10</i> genotype on venlafaxine pharmacokinetics in healthy adult volunteers

Tsuyoshi Fukuda, Isamu Yamamoto, Yuko Nishida et al. · British Journal of Clinical Pharmacology · 1999 · 95 citations · Full text

Circadian variation of the urinary 6β-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity

Masako Ohno, Ikumi Yamaguchi, Tomonobu Ito et al. · European Journal of Clinical Pharmacology · 2000 · 76 citations

Stress Hormone, Circadian Variation, Medicine +9

Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients

Masako Ohno, Akiko Yamamoto, Ayumu Ono et al. · European Journal of Clinical Pharmacology · 2009 · 57 citations

Thrombosis, Venous Thrombosis, Warfarin Dose Requirements +15